White House × Lilly × Novo: A Deep Analysis of the GLP-1 Price-Reduction Agreement — Policy Shifts, Market Reactions, and Industry Impact Introduction GLP-1–based weight-loss drugs such as Ozempic, Wegovy, and Zepbound have become the most closely watched pharmaceutical products in recent years. Beyond their powerful impact on weight management, GLP-1 therapies are rapidly expanding into cardiovascular disease, obstructive sleep apnea (OSA), NASH, addiction, and other major c
